NCT06383780

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Name: Clinical Trial NCT06383780
Creator: XIANG YANQUN
Keywords: Nasopharyngeal Carcinoma, GP combined with Tislelizumab, Phase 3, drug, clinical trial, China

A Randomized, Controlled, Multicenter Clinical Study Comparing the Efficacy of Pembrolizumab in Combination With Nab-TPC Regimen Versus the GP Regimen in the First-Line Treatment of Nasopharyngeal Carcinoma With Bone Metastases.

XIANG YANQUN·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Nasopharyngeal Carcinoma
Drug/Device/Intervention: GP combined with Tislelizumab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: XIANG YANQUN
Funder: Sun Yat-sen University
Location: Guangzhou, China

Timeline & enrollment

Phase: Phase 3
Start date: May 01, 2024
End date: May 01, 2027
Enrollment: 90 participants

Primary outcome

1-year progression-free survival rate

Summary

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

ICD-10 classifications

Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06383780
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06383780 through Pure Global AI's free database. This Phase 3 trial is sponsored by XIANG YANQUN and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.